文献速递妇科

宫内节育器使用与子宫内膜癌、宫颈癌及卵巢癌风险的关联:专家综述

Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review.
PubMed 文献 · Am J Obstet Gynecol · 2023-03-29

本文为专家综述,汇总左炔诺孕酮宫内节育器与铜宫内节育器对子宫内膜癌、宫颈癌及卵巢癌风险的影响。现有证据支持两类宫内节育器均降低子宫内膜癌风险,铜宫内节育器降低宫颈癌风险,但左炔诺孕酮宫内节育器对宫颈癌和卵巢癌风险降低的证据一致性较差。

要点

  • 左炔诺孕酮与铜宫内节育器均与子宫内膜癌风险降低相关
  • 铜宫内节育器与宫颈上皮内瘤变风险降低已明确,左炔诺孕酮宫内节育器对宫颈癌的影响尚不明确
  • 宫内节育器与卵巢癌风险关系的研究结果存在矛盾,但多数数据提示风险降低

核心结论

  • 现有证据提示左炔诺孕酮宫内节育器和铜宫内节育器均降低妇科癌症风险。
  • 激素型和铜宫内节育器降低子宫内膜癌风险、铜宫内节育器降低宫颈癌风险有证据支持,但左炔诺孕酮宫内节育器降低宫颈癌和卵巢癌风险的证据一致性较差。

研究设计与样本

  • 专家综述,汇总关于宫内节育器使用与子宫内膜癌、宫颈癌及卵巢癌关联的现有研究证据。

主要发现

  • 左炔诺孕酮宫内节育器释放孕激素导致子宫内膜抑制和宫颈黏液增厚,铜宫内节育器主要机制为局部炎症反应阻止受精。
  • 支持宫内节育器降低癌症发病率的最佳证据涉及左炔诺孕酮宫内节育器与子宫内膜癌,但研究提示铜宫内节育器和左炔诺孕酮宫内节育器均降低子宫内膜癌风险。
  • 宫内节育器与卵巢癌风险关系的研究结果存在矛盾,但多数数据提示使用者卵巢癌风险降低。
  • 铜宫内节育器使用与宫颈上皮内瘤变风险降低已明确,左炔诺孕酮宫内节育器对宫颈癌的影响尚不明确;较早研究将其使用与宫颈异型增生发病率升高关联,但较新文献发现宫内节育器使用与宫颈癌减少相关。

局限性

  • 关于宫内节育器与卵巢癌风险关系的研究结果存在矛盾。
  • 左炔诺孕酮宫内节育器对宫颈癌的影响尚不明确。
  • 支持左炔诺孕酮宫内节育器降低宫颈癌和卵巢癌风险的证据一致性较差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The intrauterine device is one of the most effective forms of contraception. Use of the intrauterine device has increased in the United States over the last 2 decades. Two formulations are commercially available in the United States: the levonorgestrel-releasing intrauterine device and the copper intrauterine device. The levonorgestrel intrauterine device releases progestin, causing endometrial suppression and cervical mucus thickening, whereas the primary mechanism of action of the copper intrauterine device is to create a local inflammatory response to prevent fertilization. Whereas the protective effects of combined hormonal contraception against ovarian and endometrial cancer, and of tubal sterilization against ovarian cancer are generally accepted, less is known about the effects of modern intrauterine devices on the development of gynecologic malignancies. The best evidence for a protective effect of intrauterine device use against cancer incidence pertains to levonorgestrel intrauterine devices and endometrial cancer, although studies suggest that both copper intrauterine devices and levonorgestrel intrauterine devices reduce endometrial cancer risk. This is supported by the proposed dual mechanisms of action including both endometrial suppression and a local inflammatory response. Studies on the relationship between intrauterine device use and ovarian cancer risk show conflicting results, although most data suggest reduced risk of ovarian cancer in intrauterine device users. The proposed biological mechanisms of ovarian cancer reduction (foreign-body inflammatory response, increased pH, antiestrogenic effect, ovulation suppression) vary by type of intrauterine device. Whereas it has been well established that use of copper intrauterine devices confers a lower risk of cervical intraepithelial neoplasms, the effect of levonorgestrel intrauterine device use on cervical cancer remains unclear. Older studies have linked its use to a higher incidence of cervical dysplasia, but more recent literature has found a decrease in cervical cancer with intrauterine device use. Various mechanisms of protection are postulated, including device-related inflammatory response in the endocervical canal and prostaglandin-mediated immunosurveillance. Overall, the available evidence suggests that both levonorgestrel intrauterine devices and copper intrauterine devices reduce gynecologic cancer risk. Whereas there is support for the reduction of endometrial cancer risk with hormonal and copper intrauterine device use, and reduction of cervical cancer risk with copper intrauterine device use, evidence in support of risk reduction with levonorgestrel intrauterine device use for cervical and ovarian cancers is less consistent.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023. PMID: 37001577. doi:10.1016/j.ajog.2023.03.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。